Myelodysplastic/Myeloproliferative Neoplasm

Myelodysplastic/Myeloproliferative Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 115
Recruiting: 70
Ph III recruiting: 3
Growth YoY: —
Industry share: 16%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 27.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (77)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04708054	Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS	recruiting	Phase 2 / Phase 3	324	M.D. Anderson Cancer CenterOTHER	1	Aug 11, 2026	clinicaltrials
NCT04256317	A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)	recruiting	Phase 2 / Phase 3	316	Taiho Oncology, Inc.INDUSTRY	10	Apr 30, 2026	clinicaltrials